The prospective multicenter TOPAZ study enrolled a heterogeneous population of 420 patients admitted to the ICU to validate the utility of [TIMP-2]*[IGFBP7] at a high-sensitivity pre-specified cut-off greater than 0.3 for the AKI defined as KDIGO stage 2 or 3 within 12 h [11]. Here, IGFBP7 is linked to acute kidney injury.